No Detail Found!

Misinterpretation of Prescription Leading to Acute Methotrexate Toxicity: An Avoidable Accident

Author(s)
Farhana Quyum BRB Hospitals Ltd.,Dhaka,Bangladesh
M.A. Bashar BRB Hospitals Ltd.,Dhaka,Bangladesh
Mashfiqul-Hasan National Institute of Neurosciences and Hospital,Dhaka,Bangladesh
Abstract
Low-dose oral methotrexate (MTX), as used for several dermatological and rheumatological indications, is generally a safe medication. Overdose of MTX may cause acute toxicity, which results in oral mucositis, skin ulceration, and pancytopenia. A 40-year-old man presented with a 3-day history of oral mucosal ulceration along with pustular eruption, painful bullae, and skin erosion. He also had a passage of black, tarry stool for 2 days. Another patient, A 50-year-old female presented with oral mucosal ulceration and per-rectal bleeding. Both were recently started on low-dose oral MTX for seronegative arthritis. Misinterpreting the physician's prescription, they took MTX daily instead of weekly. Their blood count revealed a variable degree of pancytopenia. They were treated with intravenous or oral Leucovorin, along with other supportive therapy. Patients started responding within a few days after treatment and were discharged after a week. Proper education of the patient regarding the dosage is fundamental for prescribing MTX and reducing the chance of developing toxicities. MTX-induced acute toxicity is a medical emergency requiring prompt and proper intervention.
Publication Details
Page(s) 85-87
Published Journal: Liaquat National Journal of Primary Care, Volume: 7, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
toxicity, Methotrexate, Leucovorin
References
Samarasekera E,Sawyer L,Parnham J,Smith CH .2012 .Assessment and management of psoriasis: summary of NICE guidance. BMJ, 345 : .
Menter A,Korman NJ,Elmets CA,Feldman SR,Gelfand JM,Gordon KB .2009 .Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol, 03(3) : 451-85.
Pathirana D,Ormerod AD,Saiag P,Smith C,Spuls PI,Nast A .2009 .European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol, 03389(2) : 3083-70.
Montaudié H,Sbidian E,Paul C,Maza A,Gallini A,Aractingi S .2011 .Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol, 03991 : 3083-8.
Haustein UF,Rytter M. .2000 .Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol, 00058(5) : 3083-8.
Lucas J,Ntuen E,Pearce DJ,Fleischer AB .2009 .Methotrexate: understanding the risk in psoriasis patients. J Dermatolog Treat, 20(5) : 311-3.
Olsen EA .1991 .The pharmacology of methotrexate. J Am Acad Dermatol, 25(91) : 70199-c.
Cronstein BN,Aune TM .2020 .Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol, 16(3) : 145-54.
Shen S,O'Brien T,Yap LM,Prince HM,McCormack CJ .2011 .The use of methotrexate in dermatology: a review. Australas J Dermatol, 00839(1) : 0960-18.
Roenigk HH,Auerbach R,Maibach HI,Weinstein GD .1988 .Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol, 9622(88) : 80237-8.
Dollery C .1999 .Therapeutic drugs. Edinburgh: ChurchillLivingstone, : .
Bookstaver PB,Norris L,Rudisill C,DeWitt T,Aziz S,Fant J .2008 .Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis. Am J Health Syst Pharm, 65(22) : 2117-21.
Ng HW,Macfarlane AW,Graham RM,Verbov JL .1987 .Near fatal drug interactions with methotrexate given for psoriasis. Br Med, 295(6601) : 752-3.
Hegde VS,Nagalli S. Leucovorin.,Island (FL): StatPearls Publishing S. Leucovorin. . .Updated 2023 Jul 3]. , : .
0

Citations

0

Downloads

60

Views